Nature BME:新型水凝胶,具有高粘性和药物载量,增强肌腱愈合

2022-01-06 小晶 “生物世界”公众号

研究表明,JTA可作为肌腱的强力粘合剂,用于局部延长给药,并增强肌腱滑动。

众所周知,肌腱损伤(tendon injuries)是一种常见病,损伤后肌腱功能无法完全恢复,并常伴有组织炎症和退变等并发症。虽然外科、康复、移植和药物等疗法已被用于治疗肌腱损伤,但肌腱愈合失败和持续疼痛等治疗缺陷仍然存在。

提供机械支撑和持续性药物释放疗法的水凝胶(Hydrogels)已被用于治疗肌腱损伤。然而,大多数水凝胶存在坚韧性差,且需要细胞浸润或缝合才能与周围组织融合等局限性。因此,开发具有粘性面和高载药量的坚韧水凝胶增强肌腱愈合具有重要意义。

2022年1月3日,哈佛大学和诺华公司的研究人员在 Nature 子刊 Nature Biomedical Engineering 期刊发表了题为:Enhanced tendon healing by a tough hydrogel with an adhesive side and high drug-loading capacity 的研究论文。

该研究团队设计了一种称为 Janus Tough Adhesive(JTA)的坚韧粘性水凝胶用于治疗和预防肌腱损伤,研究表明JTA表现出增强组织黏附和促进周围组织的滑动特性,此外,JTA还可作为药物递送系统用于局部药剂释放。

研究团队首先对JTA的肌腱黏附强度和组织滑动特性进行研究。JTA与牛肌腱模型接触后,壳聚糖迅速扩散到肌腱表面并产生强粘附力,黏附随着时间的推移而增加。在猪原位模型中,JTA牢固的黏附到猪髌腱,屈肌腱和跟腱中,并与组织表面很好贴合。

接下来,研究团队以人类尸体手腕为模型,测试了JTA非黏附侧的肌腱滑动的能力。JTA在掌侧板上滑动并穿过横向腕骨韧带时,表现出较低的摩擦阻力。此外,JTA在体内模型中表现出优异的生物相容性和促进肌腱愈合的能力。

接下来,研究团队以皮质类固醇曲安奈德(CORT)为药物模型,评估了JTA载药量和持续药物释放能力。JTA的CORT负载量高达CORT溶解度极限的25000倍,在体外药物释放时间超过10天。以髌腱损伤大鼠为研究模型,JTA高载药量延长了药物溶解和药物释放时间。

总的来说,该研究设计并表征了一种用于治疗和预防肌腱损伤复发的Janus Tough Adhesive(JTA)坚韧粘性水凝胶体系。除了体外研究外,JTA在多个肌腱模型中进行了原位和体内测试,研究表明,JTA可作为肌腱的强力粘合剂,用于局部延长给药,并增强肌腱滑动。具有“Janus”表面和持续药物释放功能的这款水凝胶具有巨大的临床转化的潜力。

 

原始出处:

Freedman, B.R., Kuttler, A., Beckmann, N. et al. Enhanced tendon healing by a tough hydrogel with an adhesive side and high drug-loading capacity. Nat Biomed Eng (2022). https://doi.org/10.1038/s41551-021-00810-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-04-20 cyzj007

    高科技

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-04-08 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-08 ms5000000249642182

    🤙🤙🤙

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-07 tastas
  5. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-07 lishizhe
  6. [GetPortalCommentsPageByObjectIdResponse(id=1212828, encodeId=a205121282850, content=高科技, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150625/IMG558B8C995D7262168.jpg, createdBy=36ad1623080, createdName=cyzj007, createdTime=Wed Apr 20 12:40:26 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885592, encodeId=44c41885592da, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 08 18:48:19 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182118, encodeId=9a9e1182118bd, content=🤙🤙🤙, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbf36454464, createdName=ms5000000249642182, createdTime=Sat Jan 08 09:06:31 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308086, encodeId=71b113080863c, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461089, encodeId=1be71461089f0, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512628, encodeId=9b88151262813, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Fri Jan 07 06:48:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-07 丁鹏鹏

相关资讯

J Mater Sci Mater Med:基于聚ε-赖氨酸的水凝胶基质可用于移植角膜内皮细胞的扩增

角膜内皮细胞逐渐丧失导致的角膜内皮功能障碍(CE)导致角膜水肿和严重的视力损害。目前的治疗方法是依靠供体异体组织来替代受损的CE。供体角膜的短缺要求开发生物材料,使角膜内皮细胞(CECs)在体外扩张。

超声辅助冲洗枪取出乳房内聚丙烯酰胺水凝胶临床应用

聚丙烯酰胺水凝胶(polyacrylamide hydmgel, PAHG)是一种无色透明胶冻状的液态化学合成物, 作为软组织填充材料,曾广泛应用于整形外科领 域[1]。经过远期临床应用后发现,该物质容易导致乳 房感染、变形、结节、囊肿、局部疼痛等并发症和后 遗症。因此,整形外科医师们一直致力于探索如何 彻底地取出乳房组织内的 PAHG。自 2017 年 6 月至 2019 年 6 月,中国医科大

Sci Tran Med:轻轻一涂病痛走掉,新型水凝胶预防治疗伤口感染两不误

瑞典隆德大学的研究人员基于人体的天然肽防御系统开发了一种新型水凝胶。它可以预防和治疗伤口感染,杀死多重耐药菌。

JACC:FDA I期临床试验显示,用于修复心脏的水凝胶可安全注射到人体内

最近的一项研究评估了心肌细胞外基质水凝胶,VentriGel,经心内膜注射,治疗左心室(LV)功能障碍的早期和晚期心肌梗死(MI)患者的安全性和可行性。

聚丙烯酰胺水凝胶隆乳术后 16 年 乳房罕见畸形一例报告

患者女性,42 岁, 16 年前于某整形美容医院行“双侧乳 房 PAHG 注射隆乳术”,双侧乳房注射量共 350 ml;手术顺 利,术后无明显并发症, 自觉乳房外形满意。6 年前无诱因下 发现双侧乳房增大变形,未做任何处理。

Colloids Surf B Biointerfaces:SFHs可以作为一种有效的治疗剂用于治疗肥厚性疤痕

目前治疗肥厚性疤痕的药物存在着疗效有限、恢复速度慢的瓶颈。丝纤维素(SF)因其能促进烧伤和皮肤伤口愈合而受到关注,但其对肥厚性疤痕的治疗效果尚未得到深入研究,研究结果已在线发表于Colloids Su